Stay updated on ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check16 days agoChange DetectedThe webpage has added a section with helpful links provided by Pfizer, which includes information on how to obtain contact details for a study center nearby.SummaryDifference0.3%
- Check23 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed descriptions of a clinical study involving ARRY-382 and pembrolizumab, while retaining the study's identifier and revision number.SummaryDifference12%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe webpage has removed a notice regarding heavy traffic affecting NLM-NCBI services and a link to obtain contact information for a study center provided by Pfizer.SummaryDifference0.9%
Stay in the know with updates to ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.